نتایج جستجو برای: myelogenous leukemia

تعداد نتایج: 284155  

Mohammad Kaji Yazdi, Mohammad Taghi Arzanian, Samin Alavi,

FMS-like tyrosine kinase-3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system. Mutations of FMS-like tyrosine kinase-3 have been detected in about 30% of patients with acute myelogenous leukemia and a small number of patients with acute lymphoblastic leukemia. The FMS-like tyrosine kinase-3 muta...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 2012
Yvonne Döring Oliver Soehnlein Maik Drechsler Erdenechimeg Shagdarsuren Sweena M Chaudhari Svenja Meiler Helene Hartwig Mihail Hristov Rory R Koenen Thomas Hieronymus Martin Zenke Christian Weber Alma Zernecke

OBJECTIVE Inflammatory leukocyte accumulation drives atherosclerosis. Although monocytes/macrophages and polymorphonuclear neutrophilic leukocytes (PMN) contribute to lesion formation, sequelae of myeloproliferative disease remain to be elucidated. METHODS AND RESULTS We used mice deficient in interferon regulatory factor 8 (IRF8(-/-)) in hematopoietic cells that develop a chronic myelogenous...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2004
M Golam Mohi Christina Boulton Ting-Lei Gu David W Sternberg Donna Neuberg James D Griffin D Gary Gilliland Benjamin G Neel

Abnormal protein tyrosine kinases (PTKs) cause many human leukemias. For example, BCR/ABL causes chronic myelogenous leukemia (CML), whereas FLT3 mutations contribute to the pathogenesis of acute myelogenous leukemia. The ABL inhibitor Imatinib (Gleevec, STI571) has remarkable efficacy for treating chronic phase CML, and FLT3 inhibitors (e.g., PKC412) show similar promise in preclinical studies...

Journal: :Haematologica 2013
Franck E Nicolini Amr R Ibrahim Simona Soverini Giovanni Martinelli Martin C Müller Andreas Hochhaus Inge H Dufva Dong-Wook Kim Jorge Cortes Michael J Mauro Charles Chuah Hélène Labussière Stéphane Morisset Catherine Roche-Lestienne Eric Lippert Sandrine Hayette Senaka Peter Wei Zhou Véronique Maguer-Satta Mauricette Michallet John Goldman Jane F Apperley François-Xavier Mahon David Marin Gabriel Etienne

The BCR-ABL T315I mutation confers resistance to currently licensed tyrosine kinase inhibitors in chronic myelogenous leukemia. However, the impact of this mutation on survival in early stages of disease, in chronic phase, has never been detailed. Using matched pair analysis, a cohort of 64 patients with chronic phase chronic myelogenous leukemia harboring a T315I mutation and resistant to imat...

2013
Mohammad Heydarian Moghadam Abolfazl Movafagh MirDavood Omrani Kiandokht Ghanati Mehrdad Hashemi Farhikhteh Poursafavi Hossein Darvish Davood Zare Abdolahi Milad Gholami Mohammad Reza Heidari Rostamy Shamsi Safari Leyla HaghNejad Reyhaneh Darehgazani Niloofar Safavi Naeini Mehdi Ghandehari Motlagh Davar Amani

Homogeneously staining regions (HSR) or double minute chromosomes (dmin) are autonomously replicating extra-chromosomal elements that are frequently associated with gene amplification in a variety of cancers. The diagnosis of leukemia patients was based on characterization of the leukemic cells obtained from bone marrow cytogenetics. This study report two cases, one with Acute Myeloblastic Leuk...

Journal: :Genetics and molecular research : GMR 2015
X J Wang Y H Li

To investigate the effect of treatment with resveratrol combined with imatinib mesylate on human chronic myelogenous leukemia K562 cell growth inhibition and apoptosis, in vitro cultured human chronic myelogenous leukemia K562 cells were incubated with different concentrations of resveratrol and imatinib mesylate when the cells were in the logarithmic phase. Next, the cell growth inhibition was...

Journal: :Cancer research 1994
Y Inatomi K Toyama S C Clark K Shimizu J Miyauchi

The blast progenitors in acute myelogenous leukemia grow in response to hematopoietic growth factors (HGFs), and their sensitivity to antileukemic drugs is influenced by HGFs. We report the effects of stem cell factor (SCF) on the growth and sensitivity to 1-beta-D-arabinofuranosylcytosine (Ara-C) of blast progenitors in acute myelogenous leukemia. SCF stimulated both colony formation and self-...

Journal: :Blood 1981
P B McGlave W J Miller D D Hurd D C Arthur T Kim

We performed a pilot study to test the effectiveness of allogeneic bone marrow transplantation in the treatment of chronic myelogenous leukemia. Five patients in the advanced stages of chronic myelogenous leukemia (four in blast crisis, one in accelerated phase) with abnormal chromosomes underwent matched-sibling allogeneic bone marrow transplantation after preparation with busulfan, vincristin...

2006
Moshe Talpaz Yuti Chernajovsky Karla Troutman-Worden Meir Wetzler Hagop Kantarjian Jordan U. Gutterman Razelle Kurzrock

a-Interferon induces hematological and cytogenetic remissions in some individuals with newly diagnosed Philadelphia-positive chronic myelogenous leukemia. However, interferon-resistant disease occurs in a con sistent patient subset (primary resistance) and develops during therapy in additional patients (secondary resistance). Several o-interferon-inducible genes have been characterized. In inte...

Journal: :Cancer research 1992
M Talpaz Y Chernajovsky K Troutman-Worden M Wetzler H Kantarjian J U Gutterman R Kurzrock

alpha-Interferon induces hematological and cytogenetic remissions in some individuals with newly diagnosed Philadelphia-positive chronic myelogenous leukemia. However, interferon-resistant disease occurs in a consistent patient subset (primary resistance) and develops during therapy in additional patients (secondary resistance). Several alpha-interferon-inducible genes have been characterized. ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید